Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Eli Lilly and Company
AstraZeneca
AstraZeneca
GlaxoSmithKline
Danish Gynecological Cancer Group
Merck Sharp & Dohme LLC
NETRIS Pharma
Huazhong University of Science and Technology